Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK PLC Sponsored ADR stock logo
GSK
GSK
$37.53
+1.0%
$38.96
$31.72
$44.67
$75.84B0.516.11 million shs3.68 million shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$14.17
+3.3%
$14.86
$12.80
$15.53
$43.66B0.224.71 million shs6.22 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK PLC Sponsored ADR stock logo
GSK
GSK
+1.04%-1.11%-2.57%-3.87%-3.24%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
+3.24%-2.04%-8.23%-7.51%+1.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.5092 of 5 stars
1.15.02.50.02.50.02.5
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
2.4093 of 5 stars
0.05.02.50.02.50.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.11
Hold$37.38-0.41% Downside
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest TAK and GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GSK PLC Sponsored ADR stock logo
GSK
GSK
$40.10B1.91$5.64 per share6.66$9.39 per share4.00
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$30.09B1.50$3.29 per share4.31$14.89 per share0.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GSK PLC Sponsored ADR stock logo
GSK
GSK
$3.29B$2.1617.388.071.6210.81%49.22%11.31%N/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$712.33M$0.3047.238.59N/A3.20%10.50%5.10%N/A

Latest TAK and GSK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.12$1.23+$0.11$0.94$7.92 billion$10.64 billion
5/8/2025Q4 2025
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.24$0.16-$0.08-$0.21$8.02 billion$7.34 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.714.56%N/A79.17%N/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.553.88%N/A183.33%N/A

Latest TAK and GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/31/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
5/2/2025
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42164.1%5/16/20255/16/20257/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GSK PLC Sponsored ADR stock logo
GSK
GSK
1.07
0.87
0.58
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.60
1.16
0.52

Institutional Ownership

CompanyInstitutional Ownership
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
9.17%

Insider Ownership

CompanyInsider Ownership
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.04%
CompanyEmployeesShares OutstandingFree FloatOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
68,6292.04 billion1.84 billionOptionable
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
47,4553.18 billion3.18 billionOptionable

Recent News About These Companies

Takeda revenue reduced by Vyvanse competition
Takeda Pharmaceutical 1Q Net Y124.24B Vs Net Y95.25B
IDSA Updates Guidelines on Complicated UTIs

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK stock logo

GSK NYSE:GSK

$37.53 +0.38 (+1.02%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$37.45 -0.08 (-0.21%)
As of 08/1/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Takeda Pharmaceutical stock logo

Takeda Pharmaceutical NYSE:TAK

$14.17 +0.45 (+3.28%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$14.13 -0.04 (-0.28%)
As of 08/1/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.